S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
BREAKING: Tiny biotech successfully treats blindness (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Laser breakthrough could send stock soaring 2,467% (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Laser breakthrough could send stock soaring 2,467% (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
LON:DPH

Dechra Pharmaceuticals (DPH) Share Forecast, Price & News

GBX 3,788
-8.00 (-0.21%)
(As of 09/29/2023 ET)
Compare
Today's Range
3,788
3,814
50-Day Range
3,688
3,816
52-Week Range
2,473.32
4,145.84
Volume
234,441 shs
Average Volume
916,604 shs
Market Capitalization
£4.31 billion
P/E Ratio
10,522.22
Dividend Yield
1.19%
Price Target
GBX 3,606.40

Dechra Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
4.8% Downside
GBX 3,606.40 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.00mentions of Dechra Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.84 out of 5 stars


DPH stock logo

About Dechra Pharmaceuticals (LON:DPH) Stock

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

DPH Price History

DPH Stock News Headlines

Form 8.3 - DPH LN Equity 28-September-23 Dealing Disclosure
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Form 8.3 - Dechra Pharmaceuticals plc - Amendment
Form 8.3 - DPH LN Equity 14-September-23 Dealing Disclosure
Back in the Big League: M&S Rejoins the FTSE 100 on Share Price Boost
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
DCHPF - Dechra Pharmaceuticals PLC
Form 8.3 - Dechra Pharmaceuticals PLC [DPH LN]
Form 8.3 - Dechra Pharmaceuticals
Form 8.3 - DPH LN
Form 8.3 - DECHRA PHARMA
See More Headlines
Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers—General
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
1,998
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 3,606.40
High Stock Price Forecast
GBX 4,070
Low Stock Price Forecast
GBX 2,850
Forecasted Upside/Downside
-4.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
£40.10 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£726.80 million
Cash Flow
GBX 155.05 per share
Book Value
GBX 744 per share

Miscellaneous

Free Float
N/A
Market Cap
£4.31 billion
Optionable
Not Optionable
Beta
0.79
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Ian D. Page (Age 62)
    CEO, MD & Exec. Director
    Comp: $1.26M
  • Mr. Paul Nicholas Sandland MAAT (Age 44)
    FCCA, CFO & Exec. Director
    Comp: $790k
  • Dr. Anthony Gerard Griffin (Age 60)
    MD of Dechra Veterinary Products for Europe & Exec. Director
    Comp: $601k
  • Mr. Patrick Meeus
    Group Scientific Officer
  • Mr. Jamie Adams
    Chief Information Officer
  • Ms. Katy Clough
    Group HR Director
  • Mr. Mike Eldred (Age 53)
    Pres of North America
  • Ms. Melanie Jane Hall
    Company Sec.













DPH Stock - Frequently Asked Questions

Should I buy or sell Dechra Pharmaceuticals stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dechra Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DPH shares.
View DPH analyst ratings
or view top-rated stocks.

What is Dechra Pharmaceuticals' stock price forecast for 2023?

5 Wall Street research analysts have issued 1-year price objectives for Dechra Pharmaceuticals' shares. Their DPH share price forecasts range from GBX 2,850 to GBX 4,070. On average, they predict the company's share price to reach GBX 3,606.40 in the next year. This suggests that the stock has a possible downside of 4.8%.
View analysts price targets for DPH
or view top-rated stocks among Wall Street analysts.

How have DPH shares performed in 2023?

Dechra Pharmaceuticals' stock was trading at GBX 2,618 on January 1st, 2023. Since then, DPH stock has increased by 44.7% and is now trading at GBX 3,788.
View the best growth stocks for 2023 here
.

How often does Dechra Pharmaceuticals pay dividends? What is the dividend yield for Dechra Pharmaceuticals?

Dechra Pharmaceuticals announced a dividend on Monday, February 27th. Shareholders of record on Thursday, March 9th will be paid a dividend of GBX 12.50 per share on Thursday, April 13th. This represents a dividend yield of 0.4%. The ex-dividend date is Thursday, March 9th. The official announcement can be accessed at this link.
Read our dividend analysis for DPH
.

Is Dechra Pharmaceuticals a good dividend stock?

Dechra Pharmaceuticals (LON:DPH) pays an annual dividend of GBX 45 per share and currently has a dividend yield of 1.19%. The dividend payout ratio is 12,500.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for DPH.

What other stocks do shareholders of Dechra Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Cranswick (CWK), Drax Group (DRX), RPC Group (RPC), Robert Walters (RWA), SEB (SKP) and Barratt Developments (BDEV).

What is Dechra Pharmaceuticals' stock symbol?

Dechra Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "DPH."

How do I buy shares of Dechra Pharmaceuticals?

Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Dechra Pharmaceuticals' stock price today?

One share of DPH stock can currently be purchased for approximately GBX 3,788.

How much money does Dechra Pharmaceuticals make?

Dechra Pharmaceuticals (LON:DPH) has a market capitalization of £4.31 billion and generates £726.80 million in revenue each year. The company earns £40.10 million in net income (profit) each year or GBX 0.36 on an earnings per share basis.

How many employees does Dechra Pharmaceuticals have?

The company employs 1,998 workers across the globe.

How can I contact Dechra Pharmaceuticals?

Dechra Pharmaceuticals' mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The official website for the company is www.dechra.com. The company can be reached via phone at +44-1606-814730.

This page (LON:DPH) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -